Symbols / TBPH $16.57 -0.30% Theravance Biopharma, Inc.

Healthcare • Biotechnology • United States • NGM
TBPH Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Fundamentals
Scroll to Statements
Market Cap 853.24M Enterprise Value 580.58M Income 105.89M Sales 107.46M Book/sh 5.81 Cash/sh 6.12
Dividend Yield — Payout 0.00% Employees 90 IPO — P/E 8.04 Forward P/E 12.23
PEG — P/S 7.94 P/B 2.85 P/C — EV/EBITDA -293.82 EV/Sales 5.40
Quick Ratio 10.73 Current Ratio 10.93 Debt/Eq 14.39 LT Debt/Eq — EPS (ttm) 2.06 EPS next Y 1.35
EPS Growth — Revenue Growth 144.70% Earnings 2026-05-07 ROA -0.54% ROE 44.84% ROIC —
Gross Margin 65.19% Oper. Margin 43.60% Profit Margin 98.54% Shs Outstand 51.49M Shs Float 24.13M Short Float 16.26%
Short Ratio 5.53 Short Interest — 52W High 21.03 52W Low 8.33 Beta 0.17 Avg Volume 634.38K
Volume 432.32K Target Price $17.20 Recom Buy Prev Close $16.62 Price $16.57 Change -0.30%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.20
Mean price target
2. Current target
$16.57
Latest analyst target
3. DCF / Fair value
$-1.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$16.57
Low
$15.00
High
$21.00
Mean
$17.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-07 main B. Riley Securities Neutral → Neutral $17
2026-03-23 main TD Cowen Hold → Hold $15
2026-03-20 reit BTIG Buy → Buy $21
2026-03-05 down Oppenheimer Outperform → Perform —
2026-03-04 main HC Wainwright & Co. Buy → Buy $15
2026-03-04 down B. Riley Securities Buy → Neutral $14
2026-03-03 main BTIG Buy → Buy $21
2026-03-02 main HC Wainwright & Co. Buy → Buy $27
2026-02-03 reit BTIG Buy → Buy $40
2025-12-03 init Oppenheimer — → Outperform $27
2025-11-26 main BTIG Buy → Buy $40
2025-11-11 main HC Wainwright & Co. Buy → Buy $20
2025-09-12 init B. Riley Securities — → Buy $28
2025-06-27 main BTIG Buy → Buy $25
2025-06-17 init Jones Trading — → Buy $24
2025-02-27 reit HC Wainwright & Co. Buy → Buy $15
2025-02-25 reit HC Wainwright & Co. Buy → Buy $15
2024-09-16 reit HC Wainwright & Co. Buy → Buy $15
2024-08-06 main HC Wainwright & Co. Buy → Buy $15
2024-08-06 main TD Cowen Hold → Hold $9
News
RSS: Latest TBPH news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 WINNINGHAM RICK E Chief Executive Officer — 75,000 $0.00 $0
2026-04-01 FARNUM RHONDA Officer — 18,750 $0.00 $0
2026-04-01 SAWAF AZIZ Chief Financial Officer — 37,500 $0.00 $0
2026-04-01 GRIMAUD BRETT A General Counsel — 37,500 $0.00 $0
2026-03-16 FARNUM RHONDA Officer — 31,067 $13.92 $433,637
2025-12-03 FARNUM RHONDA Officer — 31,067 $18.75 $582,501
2025-11-26 BROSHY ERAN Director — 29,501 $20.00 $590,020
2025-11-19 WINNINGHAM RICK E Chief Executive Officer — 9,900 $0.00 $0
2025-11-11 BROSHY ERAN Director — 59,000 $17.00 $1,068,250
2025-11-11 BROSHY ERAN Director — 45,000 $17.00 $809,250
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
107.46
+66.92%
64.38
+12.12%
57.42
+11.84%
51.35
Operating Revenue
107.46
+66.92%
64.38
+12.12%
57.42
+11.84%
51.35
Operating Expense
111.07
+3.98%
106.82
-3.52%
110.72
-15.14%
130.47
Research And Development
37.41
-0.61%
37.64
-7.33%
40.62
-35.92%
63.39
Selling General And Administration
73.65
+6.47%
69.17
-1.31%
70.09
+4.51%
67.07
Total Expenses
111.07
+3.98%
106.82
-3.52%
110.72
-15.14%
130.47
Operating Income
-3.60
+91.51%
-42.44
+20.37%
-53.29
+32.64%
-79.12
Total Operating Income As Reported
-3.60
+92.33%
-46.95
+16.21%
-56.03
+39.06%
-91.96
EBITDA
134.52
+449.83%
-38.45
+9.87%
-42.66
+46.28%
-79.42
Normalized EBITDA
59.38
+274.96%
-33.94
+14.98%
-39.92
+37.18%
-63.55
Reconciled Depreciation
2.81
-22.24%
3.62
-15.06%
4.26
-39.41%
7.02
EBIT
131.71
+413.08%
-42.07
+10.34%
-46.92
+45.72%
-86.45
Total Unusual Items
75.14
+1764.90%
-4.51
-64.53%
-2.74
+82.72%
-15.87
Total Unusual Items Excluding Goodwill
75.14
+1764.90%
-4.51
-64.53%
-2.74
+82.72%
-15.87
Special Income Charges
75.14
+1764.90%
-4.51
-64.53%
-2.74
+82.72%
-15.87
Other Special Charges
—
—
—
3.03
Impairment Of Capital Assets
0.00
-100.00%
4.51
0.00
—
Restructuring And Mergern Acquisition
—
0.00
-100.00%
2.74
-78.63%
12.84
Net Income
105.89
+287.70%
-56.42
-2.22%
-55.19
-106.33%
872.13
Pretax Income
129.25
+389.70%
-44.61
+9.45%
-49.27
+46.92%
-92.81
Net Non Operating Interest Income Expense
7.71
+230.28%
2.33
-65.49%
6.77
+210.94%
2.18
Interest Expense Non Operating
2.46
-3.34%
2.55
+8.34%
2.35
-63.10%
6.37
Net Interest Income
7.71
+230.28%
2.33
-65.49%
6.77
+210.94%
2.18
Interest Expense
2.46
-3.34%
2.55
+8.34%
2.35
-63.10%
6.37
Interest Income Non Operating
10.17
+108.42%
4.88
-46.46%
9.12
+6.68%
8.54
Interest Income
10.17
+108.42%
4.88
-46.46%
9.12
+6.68%
8.54
Other Income Expense
125.14
+2872.81%
-4.51
-64.53%
-2.74
+82.72%
-15.87
Other Non Operating Income Expenses
50.00
—
—
—
Tax Provision
23.35
+97.83%
11.80
+99.26%
5.92
+65722.22%
0.01
Tax Rate For Calcs
0.00
-13.95%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
13.58
+1532.61%
-0.95
-64.53%
-0.58
+82.72%
-3.33
Net Income Including Noncontrolling Interests
105.89
+287.70%
-56.42
-2.22%
-55.19
-106.33%
872.13
Net Income From Continuing Operation Net Minority Interest
105.89
+287.70%
-56.42
-2.22%
-55.19
+40.54%
-92.82
Net Income From Continuing And Discontinued Operation
105.89
+287.70%
-56.42
-2.22%
-55.19
-106.33%
872.13
Net Income Continuous Operations
105.89
+287.70%
-56.42
-2.22%
-55.19
+40.54%
-92.82
Net Income Discontinuous Operations
—
—
0.00
-100.00%
964.96
Normalized Income
44.34
+183.88%
-52.85
+0.33%
-53.03
+33.95%
-80.29
Net Income Common Stockholders
105.89
+287.70%
-56.42
-2.22%
-55.19
-106.33%
872.13
Diluted EPS
2.06
+279.13%
-1.15
-15.00%
-1.00
-108.44%
11.85
Basic EPS
2.10
+282.61%
-1.15
-15.00%
-1.00
-108.44%
11.85
Basic Average Shares
50.32
+3.01%
48.85
-11.67%
55.30
-24.85%
73.59
Diluted Average Shares
51.51
+5.45%
48.85
-11.67%
55.30
-24.85%
73.59
Diluted NI Availto Com Stockholders
105.89
+287.70%
-56.42
-2.22%
-55.19
-106.33%
872.13
Earnings From Equity Interest
—
—
—
—
Gain On Sale Of PPE
75.14
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
485.57
+37.10%
354.16
-7.29%
382.00
-37.11%
607.40
Current Assets
418.46
+159.80%
161.07
+20.61%
133.54
-62.22%
353.46
Cash Cash Equivalents And Short Term Investments
315.36
+256.94%
88.35
-13.74%
102.43
-68.72%
327.48
Cash And Cash Equivalents
167.81
+343.97%
37.80
-4.42%
39.55
-86.74%
298.17
Other Short Term Investments
147.55
+191.87%
50.55
-19.61%
62.88
+114.52%
29.31
Receivables
95.54
+39.60%
68.44
+291.67%
17.47
+4.10%
16.79
Accounts Receivable
45.54
+146.96%
18.44
+5.53%
17.47
+4.10%
16.79
Other Receivables
50.00
+0.00%
50.00
—
—
Prepaid Assets
—
0.07
-96.42%
2.04
+34.70%
1.51
Other Current Assets
7.56
+76.85%
4.28
-63.14%
11.60
+51.04%
7.68
Total Non Current Assets
67.11
-65.24%
193.09
-22.28%
248.46
-2.16%
253.94
Net PPE
30.27
-15.39%
35.77
-21.13%
45.35
-12.78%
52.00
Gross PPE
54.09
-7.02%
58.17
-13.09%
66.94
-21.10%
84.84
Accumulated Depreciation
-23.82
-6.34%
-22.40
-3.79%
-21.58
+34.27%
-32.84
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
4.40
-1.50%
4.46
+1.85%
4.38
-6.41%
4.68
Other Properties
24.41
-14.03%
28.39
-21.89%
36.35
-34.59%
55.57
Leases
25.28
-0.14%
25.32
-3.40%
26.21
+6.61%
24.58
Investments And Advances
11.13
0.00
—
0.00
Long Term Equity Investment
—
—
—
0.00
Other Non Current Assets
25.72
-83.65%
157.32
-22.54%
203.10
+0.58%
201.94
Total Liabilities Net Minority Interest
188.85
+5.73%
178.62
+5.69%
169.00
+2.06%
165.60
Current Liabilities
38.30
+19.38%
32.09
+29.55%
24.77
-13.75%
28.71
Payables And Accrued Expenses
27.36
+28.00%
21.37
+2.54%
20.84
-5.09%
21.96
Payables
7.86
-2.96%
8.10
+1.01%
8.01
+415.70%
1.55
Accounts Payable
2.57
+14.54%
2.24
+47.11%
1.52
-1.93%
1.55
Other Payable
—
—
6.49
—
Current Accrued Expenses
19.50
+46.87%
13.28
+3.49%
12.83
-37.13%
20.41
Total Tax Payable
5.29
-9.67%
5.85
0.00
—
Income Tax Payable
5.29
-9.67%
5.85
0.00
—
Current Debt And Capital Lease Obligation
10.95
+2.18%
10.71
+173.06%
3.92
-41.91%
6.75
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
10.95
+2.18%
10.71
+173.06%
3.92
-41.91%
6.75
Current Deferred Liabilities
—
—
—
0.02
Current Deferred Revenue
—
—
—
0.02
Total Non Current Liabilities Net Minority Interest
150.54
+2.74%
146.53
+1.59%
144.24
+5.37%
136.88
Long Term Debt And Capital Lease Obligation
31.76
-18.79%
39.11
-13.55%
45.24
-0.38%
45.41
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
31.76
-18.79%
39.11
-13.55%
45.24
-0.38%
45.41
Tradeand Other Payables Non Current
85.68
+13.94%
75.20
+15.17%
65.29
+1.72%
64.19
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.19
Non Current Deferred Revenue
—
—
0.00
-100.00%
0.19
Other Non Current Liabilities
33.11
+2.74%
32.22
-4.40%
33.71
+24.40%
27.09
Stockholders Equity
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Common Stock Equity
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Capital Stock
0.00
0.00
0.00
-100.00%
0.00
Common Stock
0.00
0.00
0.00
-100.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
51.07
+3.23%
49.47
+2.87%
48.09
-26.27%
65.23
Ordinary Shares Number
51.07
+3.23%
49.47
+2.87%
48.09
-26.27%
65.23
Additional Paid In Capital
1,156.29
+1.33%
1,141.06
+1.68%
1,122.16
-13.39%
1,295.72
Retained Earnings
-859.63
+10.97%
-965.52
-6.21%
-909.10
-6.46%
-853.91
Gains Losses Not Affecting Retained Earnings
0.06
+771.43%
0.01
+110.77%
-0.07
-333.33%
-0.01
Other Equity Adjustments
0.06
+771.43%
0.01
+110.77%
-0.07
-333.33%
-0.01
Total Equity Gross Minority Interest
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Total Capitalization
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Working Capital
380.16
+194.74%
128.98
+18.58%
108.77
-66.51%
324.75
Invested Capital
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Total Debt
42.70
-14.29%
49.82
+1.34%
49.16
-5.75%
52.16
Net Debt
—
—
—
—
Capital Lease Obligations
42.70
-14.29%
49.82
+1.34%
49.16
-5.75%
52.16
Net Tangible Assets
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Tangible Book Value
296.72
+69.03%
175.54
-17.58%
213.00
-51.79%
441.80
Available For Sale Securities
11.13
—
—
—
Duefrom Related Parties Current
—
—
—
0.00
Interest Payable
—
—
—
0.00
Investmentin Financial Assets
11.13
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
238.54
+2167.98%
-11.54
+57.27%
-27.00
+85.56%
-186.99
Cash Flow From Continuing Operating Activities
238.54
+2167.98%
-11.54
+57.27%
-27.00
-1013.28%
-2.42
Cash From Discontinued Operating Activities
—
—
0.00
+100.00%
-184.57
Net Income From Continuing Operations
105.89
+287.70%
-56.42
-2.22%
-55.19
+40.54%
-92.82
Depreciation Amortization Depletion
2.81
-22.24%
3.62
-15.06%
4.26
-39.41%
7.02
Depreciation
5.64
-7.89%
6.12
-0.47%
6.15
-20.14%
7.71
Amortization Cash Flow
-2.83
-12.79%
-2.51
-32.26%
-1.90
-178.56%
-0.68
Depreciation And Amortization
2.81
-22.24%
3.62
-15.06%
4.26
-39.41%
7.02
Amortization Of Intangibles
-2.83
-12.79%
-2.51
-32.26%
-1.90
-178.56%
-0.68
Other Non Cash Items
2.37
-6.83%
2.55
+8.34%
2.35
+141.27%
0.97
Stock Based Compensation
18.48
-13.64%
21.39
-15.68%
25.37
-36.15%
39.73
Asset Impairment Charge
0.00
-100.00%
4.51
0.00
—
Deferred Tax
-11.52
-52.11%
-7.57
-336.14%
3.21
0.00
Deferred Income Tax
-11.52
-52.11%
-7.57
-336.14%
3.21
0.00
Operating Gains Losses
0.04
+2.94%
0.03
-97.49%
1.35
+326.50%
0.32
Gain Loss On Sale Of PPE
0.04
+2.94%
0.03
-97.49%
1.35
+17000.00%
-0.01
Change In Working Capital
120.47
+491.85%
20.36
+344.06%
-8.34
-119.69%
42.35
Change In Receivables
-27.10
-2705.28%
-0.97
-40.20%
-0.69
+74.67%
-2.72
Changes In Account Receivables
-27.10
-2705.28%
-0.97
-40.20%
-0.69
+74.67%
-2.72
Change In Prepaid Assets
-3.29
-135.10%
9.36
+310.57%
-4.45
-155.39%
8.03
Change In Payables And Accrued Expense
4.33
+95.45%
2.22
+131.29%
-7.09
+58.16%
-16.94
Change In Accrued Expense
4.01
+173.09%
1.47
+120.69%
-7.09
+53.72%
-15.33
Change In Payable
0.33
-56.53%
0.75
+12400.00%
0.01
+100.37%
-1.61
Change In Account Payable
0.33
-56.53%
0.75
+12400.00%
0.01
+100.37%
-1.61
Change In Other Working Capital
10.48
+5.80%
9.91
+1018.06%
0.89
-98.61%
63.76
Change In Other Current Assets
143.09
+48441.55%
-0.30
+80.87%
-1.55
+81.19%
-8.23
Change In Other Current Liabilities
-7.05
-5565.12%
0.13
-97.16%
4.55
+393.48%
-1.55
Investing Cash Flow
-105.28
-957.08%
12.28
+137.57%
-32.70
-102.83%
1,154.01
Cash Flow From Continuing Investing Activities
-105.28
-957.08%
12.28
+137.57%
-32.70
-155.54%
58.88
Cash From Discontinued Investing Activities
—
—
0.00
-100.00%
1,095.13
Net PPE Purchase And Sale
-0.04
+87.35%
-0.33
+65.95%
-0.97
-175.35%
1.29
Purchase Of PPE
-0.04
+87.35%
-0.33
+86.66%
-2.49
-334.97%
-0.57
Sale Of PPE
—
0.00
-100.00%
1.51
-18.92%
1.87
Capital Expenditure
-0.04
+87.35%
-0.33
+86.66%
-2.49
-334.97%
-0.57
Net Investment Purchase And Sale
-105.24
-934.19%
12.62
+139.77%
-31.72
-157.81%
54.87
Purchase Of Investment
-248.22
-73.54%
-143.03
-6.32%
-134.53
-30.43%
-103.14
Sale Of Investment
142.97
-8.14%
155.65
+51.39%
102.81
-34.94%
158.02
Net Business Purchase And Sale
—
—
—
—
Net Other Investing Changes
—
—
—
2.71
Financing Cash Flow
-3.25
-30.08%
-2.50
+98.74%
-198.93
+73.78%
-758.81
Cash Flow From Continuing Financing Activities
-3.25
-30.08%
-2.50
+98.74%
-198.93
+73.07%
-738.62
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-631.60
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
0.00
+100.00%
-631.60
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
—
0.00
+100.00%
-631.60
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-631.60
Net Common Stock Issuance
-4.01
-33.58%
-3.00
+98.49%
-199.55
-50.86%
-132.28
Common Stock Payments
-4.03
-29.96%
-3.10
+98.44%
-199.55
-50.86%
-132.28
Repurchase Of Capital Stock
-4.03
-29.96%
-3.10
+98.44%
-199.55
-50.86%
-132.28
Proceeds From Stock Option Exercised
0.77
+50.79%
0.51
-17.80%
0.62
-22.94%
0.80
Net Other Financing Charges
—
—
—
24.46
Changes In Cash
130.01
+7537.59%
-1.75
+99.32%
-258.63
-224.21%
208.21
Beginning Cash Position
38.63
-4.33%
40.38
-86.50%
299.01
+229.32%
90.80
End Cash Position
168.64
+336.52%
38.63
-4.33%
40.38
-86.50%
299.01
Free Cash Flow
238.50
+2109.77%
-11.87
+59.75%
-29.48
+84.28%
-187.56
Interest Paid Supplemental Data
—
—
0.00
-100.00%
22.24
Income Tax Paid Supplemental Data
27.88
+25481.65%
0.11
+354.17%
0.02
-99.98%
117.97
Change In Interest Payable
—
—
0.00
+100.00%
-1.25
Common Stock Issuance
0.02
-79.80%
0.10
0.00
0.00
Earnings Losses From Equity Investments
—
—
—
—
Issuance Of Capital Stock
0.02
-79.80%
0.10
0.00
0.00
Sale Of Business
—
—
—
—
Cash From Discontinued Financing Activities
—
—
0.00
+100.00%
-20.19
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category